Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.46 |
| ▸ | ALPL | P05186 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 5/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3556990 | 0.93 | GABRA2 (0.45) | KDM4EMAPTNPC1CASP3RAB9A | |
| SCHEMBL2682560 | 0.87 | TP53 (0.48) | KDM4EMAPTNPC1CASP3RAB9A | |
| SCHEMBL3549304 | 0.86 | SRD5A2 (0.45) | KDM4EMAPTNPC1RAB9ATP53 | |
| SCHEMBL3555731 | 0.85 | CDC7 (0.46) | KDM4EMAPTNPC1RAB9ATP53 | |
| SCHEMBL12483906 | 0.80 | ALPL (0.44) | KDM4EMAPTNPC1CASP3RAB9A | |
| SCHEMBL3559754 | 0.80 | SRD5A2 (0.41) | KDM4EMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3553404 | 0.79 | CDC7 (0.45) | KDM4EMAPTNPC1RAB9ATP53 | |
| SCHEMBL5095879 | 0.78 | CNR1 (0.63) | SLC6A3CNR1CNR2 | |
| SCHEMBL476369 | 0.78 | SRD5A2 (0.45) | KDM4ENPC1RAB9ATP53MDM2 | |
| SCHEMBL2841088 | 0.76 | OPRD1 (0.58) | KDM4EMAPTNPC1CASP3RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7674821-B2 | N-[(4,5-diphenyl-3-alkyl-2-thienyl)methyl]amine [amide, sulfonamide, carbamate and urea) derivatives as cannabinoid CB1 receptor antagonists | SANOFI-AVENTIS (FR) | 2010-03-09 | — | — | US | disclosed |
| US-7462631-B2 | Thiophene-2-carboxamide derivatives, preparation and therapeutic application thereof | SANOFI-AVENTIS (FR) | 2008-12-09 | — | — | US | disclosed |
| US-20070270470-A1 | N-[(4,5-DIPHENYL-3-ALKYL-2-THIENYL)METHYL]AMINE [AMIDE, SULFONAMIDE, CARBAMATE AND UREA) DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2007-11-22 | — | — | US | disclosed |
| US-20060264470-A1 | Thiophene-2-carboxamide derivatives, preparation and therapeutic application thereof | SANOFI-AVENTIS (FR) | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264470-A1 | Thiophene-2-carboxamide derivatives, preparation and therapeutic application thereof | CNR1, CNR2, TPMT | KDM4E 691/4885MAPT 2332/4885NPC1 998/4885 |
| US-20070270470-A1 | N-[(4,5-DIPHENYL-3-ALKYL-2-THIENYL)METHYL]AMINE [AMIDE, SULFONAMIDE, CARBAMATE AND UREA) DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | CNR1, CNR2, UTS2R | KDM4E 280/4885MAPT 1915/4885NPC1 1257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.